Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 55

Posts Tagged ‘dicerna’

Dicerna™ to Present at the Jefferies 2019 Healthcare Conference

Posted by fidest press agency su giovedì, 30 maggio 2019

Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate update at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 4:00 pm EST. The conference will be held June 4-7, 2019 in New York.A live audio webcast of the presentation will be accessible within the Investors & Media section on the Dicerna website at http://www.dicerna.com. An archived replay of the webcast will be available on the Company’s website after the conference.
Dicerna™ Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between these genes and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit http://www.dicerna.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Dicerna™ to Present at the H.C. Wainwright Global Life Sciences Conference

Posted by fidest press agency su giovedì, 4 aprile 2019

Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate update at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019 at 1:40 pm GMT. The conference will be held April 7-9, 2019 in London.A live audio webcast of the presentation will be accessible within the Investors & Media section on the Dicerna website at http://www.dicerna.com. An archived replay of the webcast will be available on the Company’s website after the conference.Dicerna™ Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between these genes and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit http://www.dicerna.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences

Posted by fidest press agency su giovedì, 28 febbraio 2019

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following investor conferences in March:
8th Annual Leerink Partners Global Healthcare Conference in New York on Friday, March 1, 2019 at 9 a.m. ET.
Cowen and Company 39th Annual Healthcare Conference in Boston on Tuesday, March 12, 2019 at 8 a.m. ET.
A live audio webcast of both presentations can be accessed on the Investors and Media section of the Dicerna website at http://www.investors.dicerna.com. Archived replays will be available on the Company’s website for a period of 90 days after each conference.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit http://www.dicerna.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Dicerna Pharmaceuticals to Present at Upcoming Investor Conferences

Posted by fidest press agency su lunedì, 25 febbraio 2019

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following investor conferences in March:
8th Annual Leerink Partners Global Healthcare Conference in New York on Friday, March 1, 2019 at 9 a.m. ET. Cowen and Company 39th Annual Healthcare Conference in Boston on Tuesday, March 12, 2019 at 8 a.m. ET.
A live audio webcast of both presentations can be accessed on the Investors and Media section of the Dicerna website at http://www.investors.dicerna.com. Archived replays will be available on the Company’s website for a period of 90 days after each conference.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit http://www.dicerna.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference

Posted by fidest press agency su sabato, 7 aprile 2018

Monte Carlo, Monaco Tuesday, April 10, 2018 at 10:15 a.m. at Le Meridien Beach Plaza Hotel. Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate update at the H.C. Wainwright Global Life Sciences Conference.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit http://www.dicerna.com.

Posted in Cronaca/News, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »